QUIDELORTHO CORP Debt Securities, Available-for-sale, Amortized Cost
QUIDELORTHO CORP (QDEL) had Debt Securities, Available-for-sale, Amortized Cost of $55.90 million as of 2023-12-31, per its 10-Q filed 2024-11-08.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-11-08
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $55.90M.
- 2023-10-01: Debt Securities, Available-for-sale, Amortized Cost $56.10M.
- 2023-07-02: Debt Securities, Available-for-sale, Amortized Cost $70.30M.
- 2023-04-02: Debt Securities, Available-for-sale, Amortized Cost $77.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-12-31 | $55.90M 10-Q · filed 2024-11-08 |
| 2023-10-01 | $56.10M 10-Q · filed 2023-11-02 |
| 2023-07-02 | $70.30M 10-Q · filed 2023-08-09 |
| 2023-04-02 | $77.00M 10-Q · filed 2023-05-04 |
| 2023-01-01 | $73.80M 10-Q · filed 2023-11-02 |
| 2022-10-02 | $72.90M 10-Q · filed 2022-11-04 |
| 2022-07-03 | $68.60M 10-Q · filed 2022-08-05 |
| 2022-01-02 | $63.70M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |